Design of Hydrolytically Releasable Prodrugs for Sustained Release Nanoparticle Formulations
    5.
    发明申请
    Design of Hydrolytically Releasable Prodrugs for Sustained Release Nanoparticle Formulations 有权
    用于缓释纳米颗粒配方的水解可释放前药的设计

    公开(公告)号:US20130296285A1

    公开(公告)日:2013-11-07

    申请号:US13976776

    申请日:2011-12-28

    IPC分类号: A61K47/48

    摘要: A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.

    摘要翻译: 根据式(I)的前药,其中R2是药物的残基,所述药物具有形成COOR 2基团的羟基; Z是O或NH; m为0或1; 并且R3是包含亲油基团或聚合物残基的有机部分,条件是如果聚合物是羧甲基葡聚糖,则Z为0。 一种系统包括多个磁性纳米颗粒,包括如上所述的前体药物,能够产生支架和/或磁性纳米颗粒的暂时磁化的支架和均匀磁场源。 用药物治疗医学病症的方法包括向需要该药物的患者施用如上所述的前药,该前药能够在施用步骤后释放患者的药物。

    Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
    7.
    发明授权
    Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex 有权
    用表面附着的聚阳离子络合物配制的磁驱动的可生物降解的基因递送纳米颗粒

    公开(公告)号:US07846201B2

    公开(公告)日:2010-12-07

    申请号:US11250948

    申请日:2005-10-14

    IPC分类号: A61F2/02

    摘要: A particle including a matrix-forming agent and a polyelectrolyte-amphiphilic agent adduct wherein the polyelectrolyte-amphiphilic agent adduct is in physical communication with the matrix-forming agent. The particle further includes a coated magnetic field-responsive agent and a biomaterial. Methods of making the particle are provided. Also provided are methods of delivery of the biomaterial to a target cell or a target tissue including administering the particle having the matrix-forming agent, polyelectrolyte-amphiphilic agent adduct, the coated magnetic field-responsive agent and the biomaterial; providing a magnetic device associated with the target cell or the target tissue; applying a magnetic force to the particle; and guiding the particle toward the magnetic device by the magnetic force.

    摘要翻译: 包括基质形成剂和聚电解质 - 两亲加合物的颗粒,其中聚电解质 - 两亲性加合物与基质形成剂物理连通。 颗粒还包括涂覆的磁场响应剂和生物材料。 提供制造颗粒的方法。 还提供了将生物材料递送到靶细胞或靶组织的方法,包括施用具有基质形成剂的颗粒,聚电解质 - 两亲剂加合物,包被的磁场响应剂和生物材料; 提供与所述靶细胞或所述靶组织相关联的磁性装置; 向颗粒施加磁力; 并通过磁力将粒子引向磁性装置。

    Magnetic Gradient Targeting And Sequestering Of Therapeutic Formulations And Therapeutic Systems Thereof
    8.
    发明申请
    Magnetic Gradient Targeting And Sequestering Of Therapeutic Formulations And Therapeutic Systems Thereof 审中-公开
    治疗配方及其治疗系统的磁性梯度靶向和螯合

    公开(公告)号:US20090216320A1

    公开(公告)日:2009-08-27

    申请号:US12297971

    申请日:2007-04-20

    IPC分类号: A61M37/00 A61N2/00 A61F2/82

    摘要: A therapeutic system and a method that uses stents, and/or other implantable devices (104) for local delivery of a therapeutic agent is disclosed. A therapeutic formulation (102) may include particles of a biocompatible magnetic or magnetizable material that carry the therapeutic agent, or magnetically responsive cells. The therapeutic formulation (102) is intravenously administered to a mammalian subject. A portion of the formulation (102) is delivered to the proximity of a device (104) implanted in the vascular system of the subject by externally generating a magnetic field gradient (106) on the implantable device (104). The portion of the therapeutic formulation (102) not delivered to the proximity of the implantable device (104) is removed from the vascular system. The method allows for the repeated administration of the same or different therapeutic agent, and further, has the option of locally injecting, or alternatively, peripherally administering, the therapeutic agent.

    摘要翻译: 公开了一种治疗系统和使用支架的方法,和/或用于局部递送治疗剂的其它可植入装置(104)。 治疗剂(102)可以包括携带治疗剂或磁反应性细胞的生物相容性磁性或可磁化材料的颗粒。 将治疗制剂(102)静脉内施用于哺乳动物受试者。 制剂(102)的一部分通过在可植入装置(104)上外部产生磁场梯度(106)而输送到植入受试者的血管系统中的装置(104)附近。 从血管系统中去除未被输送到可植入装置(104)附近的部分治疗剂(102)。 该方法允许相同或不同的治疗剂的重复给药,此外,还可以选择局部注射或替代地外周施用治疗剂。

    Hydrolytically releasable prodrugs for sustained release nanoparticle formulations
    9.
    发明授权
    Hydrolytically releasable prodrugs for sustained release nanoparticle formulations 有权
    用于缓释纳米颗粒制剂的水解可释放的前药

    公开(公告)号:US09233163B2

    公开(公告)日:2016-01-12

    申请号:US13976776

    申请日:2011-12-28

    IPC分类号: A61K47/48 C08B37/02

    摘要: A prodrug according to formula (I) wherein R2 is a residue of a drug, said drug having a hydroxyl group by which the COOR2 group is formed; Z is O or NH; m is 0 or 1; and R3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.

    摘要翻译: 根据式(I)的前药,其中R2是药物的残基,所述药物具有形成COOR 2基团的羟基; Z是O或NH; m为0或1; 并且R3是包含亲油基团或聚合物残基的有机部分,条件是如果聚合物是羧甲基葡聚糖,则Z为0。 一种系统包括多个磁性纳米颗粒,包括如上所述的前体药物,能够产生支架和/或磁性纳米颗粒的暂时磁化的支架和均匀磁场源。 用药物治疗医学病症的方法包括向需要该药物的患者施用如上所述的前药,该前药能够在施用步骤后释放患者的药物。

    Magnetic targeting device, system and method
    10.
    发明授权
    Magnetic targeting device, system and method 有权
    磁性靶向装置,系统及方法

    公开(公告)号:US09084877B2

    公开(公告)日:2015-07-21

    申请号:US13883054

    申请日:2011-10-27

    摘要: A treatment system includes a magnetic targeting catheter and a plurality of MNP. The MNP may include one or more magnetic field-responsive agents and one or more therapeutic agents. The catheter may include an inner shaft having at least one lumen and a fluid delivery balloon adapted to administer a fluid from the inner shaft into a space surrounding the catheter. An expandable mesh formed of a magnetizable material may surround the fluid delivery balloon. The catheter may further include one or more occlusion balloons for controlling blood flow through a vessel in which the catheter is placed. A method of treating a medical condition may include advancing a magnetic targeting catheter to a site, deploying an expandable mesh connected to the catheter, applying a magnetic field to the mesh and depositing a plurality of MNP or cells loaded with MNP near the mesh.

    摘要翻译: 治疗系统包括磁性靶向导管和多个MNP。 MNP可以包括一种或多种磁场响应剂和一种或多种治疗剂。 导管可以包括具有至少一个内腔的内轴和适于将流体从内轴施加到围绕导管的空间的流体输送球囊。 由可磁化材料形成的可膨胀网可围绕流体输送球囊。 导管还可以包括一个或多个阻塞气囊,用于控制通过其中放置导管的血管的血流。 治疗医疗状况的方法可以包括将磁性靶向导管推进到位置,展开连接到导管的可扩张网,向网状物施加磁场并且在网格附近沉积多个MNP或装载有MNP的细胞。